Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Sony Group Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Sony Group Corp trades at $20.8 (market cap $122.79B). The key difference: Sony Group Corp is far larger — about 15.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Sony Group Corp pays a 0.76% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SONY | |
|---|---|---|
Market Cap | $8.04B | $122.79B |
Sector | Health | Technology |
52-Week High | $339.75 | $30.26 |
52-Week Low | $241.71 | $19.32 |
Enterprise Value | $7.85B | $119.28B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Sony trades at $20.68, down 0.82% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong operating cash flow of $2.32 trillion for 2025 and maintains solid valuation metrics including a P/E of 19.51. Recent news highlights Sony's strategic shift to digital-only PlayStation games by 2028 and conditional approval for a U.S. stablecoin bank.
Outlook remains mixed with analyst consensus strongly bullish (69% buy ratings) but near-term earnings volatility. Key opportunities include digital transformation and financial services expansion, while risks involve execution of digital strategy and projected net income decline to -$326.9 billion for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
